5

10

Abstract

Tumour vaccine and process for the preparation thereof. The tumour vaccine contains tumour cells at least some of which contain at least one MHC-I-haplotype of the patient on the cell surface, and which are charged with one or more peptides binding to the MHC-I molecule in such a way that the tumour cells are recognised as foreign by the patient's immune system in context with the peptides and trigger a cellular immune response. The charging is carried out in the presence of a polycation such as polylysine.